Page 91 - Read Online

Michaelis et al. Cancer Drug Resist 2019;2:447-56 I http://dx.doi.org/10.20517/cdr.2019.005 Page 455

inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug resistant cancer cells. Cell Death Dis 2011;2:e243.
67. Jones RJ, Bjorklund CC, Baladandayuthapani V, Kuhn DJ, Orlowski RZ. Drug resistance to inhibitors of the human double minute-2 E3
ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA. Mol Cancer Ther 2012;11:2243-53.
68. Michaelis M, Rothweiler F, Agha B, Barth S, Voges Y, et al. Human neuroblastoma cells with acquired resistance to the p53 activator
RITA retain functional p53 and sensitivity to other p53 activating agents. Cell Death Dis 2012;3:e294.
69. Hoffman-Luca CG, Ziazadeh D, McEachern D, Zhao Y, Sun W, et al. Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors
in Acute Leukemia In Vitro and In Vivo. Clin Cancer Res 2015;21:2558-68.
70. Drummond CJ, Esfandiari A, Liu J, Lu X, Hutton C, et al. TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53
binding antagonists retain sensitivity to ionizing radiation. Oncotarget 2016;7:46203-18.
71. Jung J, Lee JS, Dickson MA, Schwartz GK, Le Cesne A, et al. TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in
de-differentiated liposarcoma. Nat Commun 2016;7:12609.
72. Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, Castillo-Martin M, Quinn SA, et al. Suppression of acquired docetaxel resistance in
prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell 2012;22:373-88.
73. Zahreddine HA, Culjkovic-Kraljacic B, Assouline S, Gendron P, Romeo AA, et al. The sonic hedgehog factor GLI1 imparts drug
resistance through inducible glucuronidation. Nature 2014;511:90-3.
74. Göllner S, Oellerich T, Agrawal-Singh S, Schenk T, Klein HU, et al. Loss of the histone methyltransferase EZH2 induces resistance to
multiple drugs in acute myeloid leukemia. Nat Med 2017;23:69-78.
75. Schneider C, Oellerich T, Baldauf HM, Schwarz SM, Thomas D, et al. SAMHD1 is a biomarker for cytarabine response and a therapeutic
target in acute myeloid leukemia. Nat Med 2017;23:250-5.
76. Malani D, Murumägi A, Yadav B, Kontro M, Eldfors S, et al.. Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML.
Leukemia 2017;31:1187-95.
77. Benedetti V, Perego P, Luca Beretta G, Corna E, Tinelli S, et al. Modulation of survival pathways in ovarian carcinoma cell lines resistant
to platinum compounds. Mol Cancer Ther 2008;7:679-87.
78. Cossa G, Lanzi C, Cassinelli G, Carenini N, Arrighetti N, et al. Differential outcome of MEK1/2 inhibitor-platinum combinations in
platinum-sensitive and -resistant ovarian carcinoma cells. Cancer Lett 2014;347:212-24.
79. McGranahan N, Swanton C. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell 2017;168:613-28.
80. Greaves M. Nothing in cancer makes sense except… BMC Biol 2018;16:22.
81. Stanta G, Bonin S. Overview on Clinical Relevance of Intra-Tumor Heterogeneity. Front Med (Lausanne) 2018;5:85.
82. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, et al. Genotypic and histological evolution of lung cancers
acquiring resistance to EGFR Inhibitors. Sci Transl Med 2011;3:75ra26.
83. Jun HJ, Acquaviva J, Chi D, Lessard J, Zhu H, et al. Acquired MET expression confers resistance to EGFR inhibition in a mouse model
of glioblastoma multiforme. Oncogene 2012;31:3039-50.
84. Basile KJ, Abel EV, Dadpey N, Hartsough EJ, Fortina P, et al. In vivo MAPK reporting reveals the heterogeneity in tumoral selection of
resistance to RAF inhibitors. Cancer Res 2013;73:7101-10.
85. Patel C, Stenke L, Varma S, Lindberg ML, Björkholm M, ey al. Multidrug resistance in relapsed acute myeloid leukemia: evidence of
biological heterogeneity. Cancer 2013;119:3076-83.
86. Kemper K, Krijgsman O, Cornelissen-Steijger P, Shahrabi A, Weeber F, et al. Intra- and inter-tumor heterogeneity in a vemurafenib-
resistant melanoma patient and derived xenografts. EMBO Mol Med 2015;7:1104-18.
87. Soucheray M, Capelletti M, Pulido I, Kuang Y, Paweletz CP, et al. Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in
Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition. Cancer Res 2015;75:4372-83.
88. Quéré G, Descourt R, Robinet G, Autret S, Raguenes O, et al. Mutational status of synchronous and metachronous tumor samples in
patients with metastatic non-small-cell lung cancer. BMC Cancer 2016;16:210.
89. Litzenburger UM, Buenrostro JD, Wu B, Shen Y, Sheffield NC, et al. Single-cell epigenomic variability reveals functional cancer
heterogeneity. Genome Biol 2017;18:15.
90. Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE. Drug-selected human lung cancer stem cells: cytokine network,
tumorigenic and metastatic properties. PLoS One 2008;3:e3077.
91. Aziz MH, Shen H, Maki CG. Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3. Oncogene
2011;30:4678-86.
92. Little AS, Balmanno K, Sale MJ, Newman S, Dry JR, et al. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired
resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci Signal 2011;4:ra17.
93. Hata AN, Niederst MJ, Archibald HL, Gomez-Caraballo M, Siddiqui FM, et al. Tumor cells can follow distinct evolutionary paths to
become resistant to epidermal growth factor receptor inhibition. Nat Med 2016;22:262-9.
94. Brady SW, McQuerry JA, Qiao Y, Piccolo SR, Shrestha G, et al. Combating subclonal evolution of resistant cancer phenotypes. Nat
Commun 2017;8:1231.
95. Hata AN, Rowley S, Archibald HL, Gomez-Caraballo M, Siddiqui FM, et al. Synergistic activity and heterogeneous acquired resistance
of combined MDM2 and MEK inhibition in KRAS mutant cancers. Oncogene 2017;36:6581-91.
96. Kim C, Gao R, Sei E, Brandt R, Hartman J, et al. Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell
Sequencing. Cell 2018;173:879-893.e13.
97. Liu Y, Li Y, Ou Q, Wu X, Wang X, et al. Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung
cancer but retains sensitivity to afatinib. Lung Cancer 2018;118:1-5.